by Truveta staff | Dec 15, 2023 | Research
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
by Truveta Research | Nov 10, 2023 | Research, Research Insights
Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
by Truveta staff | Jun 15, 2023 | Data
We are entering a new era of Alzheimer’s Disease research. Researchers from the University of Tsukuba in Japan along with IBM Research have recently developed a mobile app to detect Alzheimer’s using speech data. New research suggests deep brain stimulation while...
by Truveta Research | Apr 21, 2023 | Research, Research Insights
The National Institute of Health estimates that more than six million Americans over the age of 65 suffer from Alzheimer’s disease, with many more under the age of 65 also having the disease (National Institute on Aging, 2021). It is currently ranked as the seventh...
